GR1008818B - Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου - Google Patents

Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου

Info

Publication number
GR1008818B
GR1008818B GR20150100238A GR20150100238A GR1008818B GR 1008818 B GR1008818 B GR 1008818B GR 20150100238 A GR20150100238 A GR 20150100238A GR 20150100238 A GR20150100238 A GR 20150100238A GR 1008818 B GR1008818 B GR 1008818B
Authority
GR
Greece
Prior art keywords
antifungal agent
preparation
pharmaceutical composition
composition containing
echinocandin antifungal
Prior art date
Application number
GR20150100238A
Other languages
English (en)
Inventor
Ευθυμιος Χρηστου Κουτρης
Ιωαννα Χρηστου Κουτρη
Αναστασια Λεωνιδα Καλασκανη
Βασιλικη Χρηστου Σαμαρα
Ανδρεας Κωνσταντινου Κακουρης
Γιωργος Θεμιστοκλη Γκοτζαμανης
Ευαγγελος Ανδρεα Καραβας
Χριστινα-Χρυση Ηλια Κιζιριδη
Original Assignee
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων filed Critical Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων
Priority to GR20150100238A priority Critical patent/GR1008818B/el
Priority to PCT/EP2016/000840 priority patent/WO2016188625A1/en
Priority to EP16728831.5A priority patent/EP3298026A1/en
Publication of GR1008818B publication Critical patent/GR1008818B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά υδατικό διάλυμα περιέχον έναν αντιμυκητιασιακό παράγοντα εχινοκανδίνης, όπως η οξική Κασποφουνγκίνη, ως δραστική ουσία, ένα ρυθμιστικό μέσο και τουλάχιστον ένα αραιωτικό/διογκωτικό. Επίσης, αφορά τη λυοφιλοποίηση τέτοιου διαλύματος, ώστε να ανακτηθεί μια ξηρή κόνις για ανασύσταση πριν τη χρήση.
GR20150100238A 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου GR1008818B (el)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GR20150100238A GR1008818B (el) 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
PCT/EP2016/000840 WO2016188625A1 (en) 2015-05-22 2016-05-20 Pharmaceutical composition containing an echinocandin antifungal agent and method for the preparation thereof
EP16728831.5A EP3298026A1 (en) 2015-05-22 2016-05-20 Pharmaceutical composition containing an echinocandin antifungal agent and method for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20150100238A GR1008818B (el) 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου

Publications (1)

Publication Number Publication Date
GR1008818B true GR1008818B (el) 2016-08-01

Family

ID=56121013

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20150100238A GR1008818B (el) 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου

Country Status (3)

Country Link
EP (1) EP3298026A1 (el)
GR (1) GR1008818B (el)
WO (1) WO2016188625A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
HK1040062A1 (zh) 1999-03-03 2002-05-24 Eli Lilly And Company 含有成胶束表面活性剂的棘白菌素药物配方
WO2009002481A1 (en) * 2007-06-26 2008-12-31 Merck & Co., Inc. Lyophilized anti-fungal composition
AU2011304408B2 (en) * 2010-09-20 2015-01-15 Xellia Pharmaceuticals Aps Caspofungin composition
CN103212058A (zh) * 2012-01-18 2013-07-24 江苏恒瑞医药股份有限公司 含有抗真菌药物和乳酸盐缓冲剂的组合物
CN103315966B (zh) * 2013-06-18 2016-01-13 江苏奥赛康药业股份有限公司 一种注射用醋酸卡泊芬净药物组合物及其制备方法

Also Published As

Publication number Publication date
EP3298026A1 (en) 2018-03-28
WO2016188625A9 (en) 2017-04-27
WO2016188625A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
PH12014502778B1 (en) Antibody formulation
MY187047A (en) Selective pyy compounds and uses thereof
MY185802A (en) Antibody formulation
ZA201906451B (en) 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same
WO2015058173A8 (en) Stable solid units and methods of making the same
IN2013MU03583A (el)
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
PH12017500450A1 (en) Flavivirus virus like particle
MX2020012989A (es) Agente terapeutico para la fibrosis.
TW201613557A (en) Stable aqueous recombinant protein formulations
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EP3192368A4 (en) Composition for preserving cells, containing, as active ingredients, plant-derived recombinant human serum albumin and plant peptides
GR1008234B (el) Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου
GR1008818B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
EP3323411A4 (en) Composition for inhibiting angiogenesis containing nanoparticle-vitreous body-based protein complex as active ingredient, and use thereof
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
EP3210614A4 (en) Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
EA201500694A1 (ru) Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов
IN2014MU00284A (el)
MD20170094A2 (ro) Procedeu de fabricare a amestecurilor de pulbere uscată
ZA201801839B (en) Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof
PH12018501392A1 (en) Pharmaceutical composite preparation

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20160921